GlassScriptPhysician profile
Zain Ahmed
NPI 1952782567
$8,907.86
in general payments reported to CMS, 2019-2025
24 companies · $6,128 in 2025
The $6,128 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $1,372 · 2023: $416 · 2024: $829 · 2025: $6,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,604 · Travel and Lodging: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,603.77 |
| Travel and Lodging | $2,769.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,581.62 | 2021-2025 | Symplicity G3, Mo.Ma Ultra, Turbohawk |
| Abbott Laboratories | $3,045.88 | 2021-2025 | Perclose Proglide, Xience Skypoint, Cardiomems |
| Bard Peripheral Vascular, INC. | $357.47 | 2025 | Crosser Iq, Fluency Endovascular Stent Graft, Lutonix Drug Coated Balloon |
| Shockwave Medical, INC | $278.78 | 2025 | |
| Novo Nordisk INC | $278.37 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $181.03 | 2024 | Arcalyst |
| Pfizer INC. | $152.88 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $152.20 | 2023-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $110.81 | 2022-2025 | Farxiga, Wainua |
| Esperion Therapeutics, INC. | $89.12 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $84.76 | 2024-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $81.08 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Amgen INC. | $75.63 | 2022-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $65.11 | 2023 | Xarelto |
| Cardiva Medical, INC. | $61.17 | 2025 | Cardiva Vascade 6/7f Vcs |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.60 | 2024 | |
| Sanofi-Aventis U.S. LLC | $56.05 | 2022-2023 | |
| Boston Scientific Corporation | $41.72 | 2025 | Varithena Administration Pack |
| Cvrx, INC. | $41.63 | 2023 | Barostim Neo System |
| Inspire Medical Systems, INC. | $32.74 | 2025 | Inspire |
| Impulse Dynamics (USA) INC. | $25.34 | 2022 | |
| Bracco Diagnostics INC. | $25.02 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.83 | 2024 | Lifevest |
| Biomerieux INC | $15.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zain Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.